Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective study of upadacitinib in moderate-to-severe Crohn's disease
ChiCTR2500098312Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Clinical response rate, Clinical remission rate and 5 more. Started Mar 2025; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500098312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098312.